Nymox Pharmaceutical (NASDAQ: NYMX) specializes in the research and development of therapeutics and diagnostics, with an emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The company’s lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. The company will soon be filing for approval in major economies around the world, including the United States and Europe. In addition, the Company is developing Fexapotide for early-stage, non-aggressive prostate cancer (PCA). For more information, visit the company’s website at www.nymox.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
